iTeos Therapeutics (ITOS) Price & Analysis

Compare

196 Followers

ITOS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.80 - $17.63

Previous CloseN/A

Volume59.28K

Average Volume (3M)1.42M

Market Cap

$447.80M

Enterprise Value-$75.96M

Total Cash (Recent Filing)$515.43M

Total Debt (Recent Filing)$5.13M

Price to Earnings (P/E)―

Beta1.68

Next Earnings

Nov 05, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.81

Shares Outstanding44,205,400

10 Day Avg. Volume1,016,564

30 Day Avg. Volume1,424,252

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.17

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit2.17

Enterprise Value/Ebitda0.38

Forecast

1Y Price Target

$10.76

Price Target Upside6.22% Upside

Rating ConsensusHold

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

AcquisitionThe acquisition by Concentra Biosciences is likely to close with the top two shareholders, EcoR1 and Tang Capital, in a positive position.

Cash PositionITeos ended with cash of $624 million, indicating a strong cash position before the acquisition.

Stock PerformanceThe stock is up 18% pre-market, reflecting optimism despite the recent changes.

Bears Say

Legal DisputesThe deal lacks a provision for shareholder vote, which may lead to legal disputes similar to other Concentra deals.

Pipeline DevelopmentThere is low confidence that any early-stage immuno-oncology asset will add value for iTeos, as the investor bar for excitement is high.

Shareholder ExpectationsThe terms of the acquisition may not meet broader shareholder expectations, being approximately 30% to previously disclosed iTeos cash.

iTeos Therapeutics News

GSK and iTeos Advance Immunotherapy Study for Lung Cancer

GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)), Iteos Therapeutics, Inc. (($ITOS)) announced an update on their ongoing clinical study....

14d ago

GSK

ITOS

GSK and iTeos Therapeutics’ Promising Phase 3 Lung Cancer Study: Market Implications

GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)), Iteos Therapeutics, Inc. (($ITOS)) announced an update on their ongoing clinical study....

21d ago

GSK

ITOS

iTeos Therapeutics Faces Challenges Amid Collaboration Termination

Iteos Therapeutics, Inc. ( ($ITOS) ) has released its Q2 earnings. Here is a breakdown of the information...

22d ago

ITOS

iTeos Therapeutics downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler analyst Edward Tenthoff downgraded iTeos Therapeutics (ITOS) to Neutral from Overweight with a price target of...

1M ago

ITOS

Vor Bio appoints Cumbo, Detheux to board of directors

Vor Bio (VOR) announced the appointment of Alexander Cumbo and Michel Detheux, Ph.D., to its Board of Directors,...

1M ago

VOR

ITOS

iTeos Therapeutics Announces Merger with Concentra Biosciences

iTeos Therapeutics ( ($ITOS) ) has issued an announcement. On July 18, 2025, iTeos Therapeutics entered into a...

1M ago

ITOS

iTeos to be acquired by Concentra for $10.047 per share in cash plus CVR

iTeos Therapeutics (ITOS) entered into a definitive merger agreement whereby Concentra Biosciences will acquire iTeos for $10.047 in...

1M ago

ITOS

GSK and Iteos Therapeutics’ Promising Phase 3 Study on NSCLC Treatment

GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)), Iteos Therapeutics, Inc. (($ITOS)) announced an update on their ongoing clinical study....

1M ago

GSK

ITOS

GSK and iTeos Therapeutics Advance Phase 3 NSCLC Study with Belrestotug and Dostarlimab

GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)), Iteos Therapeutics, Inc. (($ITOS)) announced an update on their ongoing clinical study....

1M ago

GSK

ITOS

iTeos Therapeutics Holds Annual Stockholders Meeting

The latest announcement is out from iTeos Therapeutics ( ($ITOS) ). iTeos Therapeutics, Inc. held its Annual Meeting...

2M ago

ITOS

Tim Van Hauwermeiren Resigns from iTeos Board

iTeos Therapeutics ( ($ITOS) ) has shared an update. On June 1, 2025, Tim Van Hauwermeiren resigned from...

3M ago

ITOS

iTeos Therapeutics: Strategic Wind Down to Maximize Shareholder Value Amid Limited Pipeline Prospects

Analyst Daina Graybosch of Leerink Partners reiterated a Hold rating on iTeos Therapeutics (ITOS – Research Report), boosting...

3M ago

ITOS

iTeos Therapeutics downgraded to Equal Weight at Wells Fargo on wind down

As previously reported, Wells Fargo analyst Eva Fortea Verdejo downgraded iTeos Therapeutics (ITOS) to Equal Weight from Overweight...

3M ago

ITOS

iTeos Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo

Wells Fargo downgraded iTeos Therapeutics (ITOS) to Equal Weight from Overweight with a $12 price target Published first...

3M ago

ITOS

ITOS FAQ

What was iTeos Therapeutics’s price range in the past 12 months?

iTeos Therapeutics lowest stock price was $4.80 and its highest was $17.63 in the past 12 months.

What is iTeos Therapeutics’s market cap?

iTeos Therapeutics’s market cap is $447.80M.

When is iTeos Therapeutics’s upcoming earnings report date?

iTeos Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 68 days.

How were iTeos Therapeutics’s earnings last quarter?

iTeos Therapeutics released its earnings results on Aug 06, 2025. The company reported -$1.807 earnings per share for the quarter, missing the consensus estimate of -$1.392 by -$0.415.

Is iTeos Therapeutics overvalued?

According to Wall Street analysts iTeos Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does iTeos Therapeutics pay dividends?

iTeos Therapeutics does not currently pay dividends.

What is iTeos Therapeutics’s EPS estimate?

iTeos Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does iTeos Therapeutics have?

iTeos Therapeutics has 44,205,400 shares outstanding.

What happened to iTeos Therapeutics’s price movement after its last earnings report?

iTeos Therapeutics reported an EPS of -$1.807 in its last earnings report, missing expectations of -$1.392. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of iTeos Therapeutics?

Currently, no hedge funds are holding shares in ITOS

iTeos Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-34.97%

Trailing 12-Months

Asset Growth

-17.13%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

iTeos Therapeutics

iTeos Therapeutics (ITOS) is a biotechnology company dedicated to the discovery and development of novel cancer immunotherapies. The company operates primarily in the pharmaceutical and biotechnology sectors, focusing on creating innovative treatments that harness the body's immune system to fight cancer. Its core products are centered around immuno-oncology drug candidates designed to target specific pathways involved in immune resistance and tumor growth.

iTeos Therapeutics (ITOS) Earnings & Revenues

Historic Earnings Reports

ITOS Stock 12 Month Forecast

Average Price Target

$10.76

▲(6.22% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","11":"$11","18":"$18","7.5":"$7.5","14.5":"$14.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.76,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,7.5,11,14.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.09,10.236923076923077,10.383846153846154,10.53076923076923,10.677692307692308,10.824615384615385,10.971538461538461,11.118461538461538,11.265384615384615,11.412307692307692,11.55923076923077,11.706153846153846,11.853076923076923,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.09,10.141538461538461,10.193076923076923,10.244615384615384,10.296153846153846,10.347692307692308,10.399230769230769,10.45076923076923,10.502307692307692,10.553846153846154,10.605384615384615,10.656923076923077,10.708461538461538,{"y":10.76,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.09,10.083076923076923,10.076153846153845,10.069230769230769,10.062307692307693,10.055384615384614,10.048461538461538,10.041538461538462,10.034615384615385,10.027692307692307,10.02076923076923,10.013846153846155,10.006923076923076,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.27,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.78,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.74,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.46,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.81,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.68,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >